Discover

Never-approved oncology programs that may still have value

This list is for licensing a shelved compound that never reached a US label. FDA-approved drugs are excluded — a terminated trial of a marketed product is a new-indication study, not an abandoned asset. Ranked by recoverability, novelty, clinical importance, IP, and dealability, not a single opaque score. A recoverable failure is a reason to open the file, not a conclusion the asset is valuable.

FailureRecoverabilityPhaseNever-approved only

2 never-approved opportunities · loading live corpus…

Internal rank uses published weights. Sort any column.

																	Save
MRTX-1133 ReferenceNCT05737706	Bristol Myers Squibb (via the 2023 Mirati acquisition) was Mirati Therapeutics	KRAS G12D	Reversible, non-covalent, dual-state KRAS G12D inhibitor	Phase 1 of a Phase 1/2 multiple-expansion-cohort trial (63 participants treated). ClinicalTrials.gov records it as Phase 1, terminated 10 Mar 2025; the expansion cohorts never opened.	KRAS G12D solid tumors — pancreatic ductal adenocarcinoma first, also colorectal and NSCLC	Terminated / discontinued (public)	Formulation	Unknown	Low	Potentially recoverable	High	High	High	Moderate	Moderate	NCT05737706 — “A Phase 1/2 Multiple Expansion Co
TLY012 Reference	D&D Pharmatech / Theraly Fibrosis was Theraly Fibrosis (D&D Pharmatech)	DR5 (TRAIL-R2)	Engineered, PEGylated trimeric recombinant human TRAIL (TNF-related apoptosis-inducing ligand); agonist of death receptor DR5 (TRAIL-R2), a tumor-selective apoptosis pathway	US Phase 1 IND cleared, per the company pipeline, with two FDA Orphan Drug Designations granted in 2020. ClinicalTrials.gov lists no TLY012 study at all (intervention search, 14 Sep 2026), so no patient dosing is on the public record.	DR5-expressing gastrointestinal cancers — pancreatic ductal adenocarcinoma and gastric adenocarcinoma in the published preclinical work. The two existing FDA orphan designations are in fibrotic disease: systemic sclerosis and chronic pancreatitis.	Stalled — no completed interventional NCT	Strategic reprioritization	Moderate	Unknown	Potentially recoverable	High	High	Moderate	Moderate	Moderate	No TLY012 study registered — intervention search

Never-approved oncology programs that may still have value

MRTX-1133

ReferenceNCT05737706

Bristol Myers Squibb (via the 2023 Mirati acquisition)

was Mirati Therapeutics

KRAS G12D

Reversible, non-covalent, dual-state KRAS G12D inhibitor

Phase 1 of a Phase 1/2 multiple-expansion-cohort trial (63 participants treated). ClinicalTrials.gov records it as Phase 1, terminated 10 Mar 2025; the expansion cohorts never opened.

KRAS G12D solid tumors — pancreatic ductal adenocarcinoma first, also colorectal and NSCLC

Terminated / discontinued (public)

Formulation

Unknown

Low

Potentially recoverable

High

Moderate

NCT05737706 — “A Phase 1/2 Multiple Expansion Co

TLY012

Reference

D&D Pharmatech / Theraly Fibrosis

was Theraly Fibrosis (D&D Pharmatech)

DR5 (TRAIL-R2)

Engineered, PEGylated trimeric recombinant human TRAIL (TNF-related apoptosis-inducing ligand); agonist of death receptor DR5 (TRAIL-R2), a tumor-selective apoptosis pathway

US Phase 1 IND cleared, per the company pipeline, with two FDA Orphan Drug Designations granted in 2020. ClinicalTrials.gov lists no TLY012 study at all (intervention search, 14 Sep 2026), so no patient dosing is on the public record.

DR5-expressing gastrointestinal cancers — pancreatic ductal adenocarcinoma and gastric adenocarcinoma in the published preclinical work. The two existing FDA orphan designations are in fibrotic disease: systemic sclerosis and chronic pancreatitis.

Stalled — no completed interventional NCT

Strategic reprioritization

Moderate

Unknown

Potentially recoverable

High

Moderate

No TLY012 study registered — intervention search